[1]
Farooqi, A.A.; Fayyaz, S.; Poltronieri, P.; Calin, G.A.; Mallardo, M. Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs. Seminars Cancer Biol. Epub ahead of print, 30.7.2020, pii: S1044579X-2030170X. doi: 10.1016/j.semcancer.2020.07.013
[2]
Poltronieri, P.; Xu, B.; Giovinazzo, G. Resveratrol and other stilbenes: Effects on dysregulated gene expression in cancers and novel delivery systems. Anticancer. Agents Med. Chem., 2020. Epub ahead of print
[http://dx.doi.org/10.2174/1871520620666200705220722]
[http://dx.doi.org/10.2174/1871520620666200705220722]
[3]
Neganova, M.E.; Klochkov, S.G.; Aleksandrova, Y.R.; Osipov, V.N.; Avdeev, D.V.; Pukhov, S.A.; Gromyko, A.V.; Aliev, G. New spirocyclic hydroxamic acids as effective antiproliferative agents. Anticancer. Agents Med. Chem., 2020. Epub ahead of print
[http://dx.doi.org/10.2174/1871520620666200527132420]
[http://dx.doi.org/10.2174/1871520620666200527132420]
[4]
Dandawate, P.; Ahmed, K.; Padhye, S.; Ahmad, A.; Biersack, B. Anticancer active heterocyclic chalcones: Recent developments. Anticancer. Agents Med. Chem., 2020. Epub ahead of print
[http://dx.doi.org/10.2174/1871520620666200705215722]
[http://dx.doi.org/10.2174/1871520620666200705215722]
[5]
Martinelli, C. Smart Nanocarriers for Targeted Cancer Therapy. Anticancer. Agents Med. Chem., 2020. Epub ahead of print
[http://dx.doi.org/10.2174/1871520620666200619181425]
[http://dx.doi.org/10.2174/1871520620666200619181425]
[6]
Pourhanifeh, M.H.; Mottaghi, R.; Sadat, R.Z.; Shafiee, A.; Hajighadimi, S.; Mirzaei, H. Therapeutic applications of curcumin and its novel formulations in the treatment of bladder cancer: A review of current evidence. Anticancer. Agents Med. Chem., 2020. Epub ahead of print
[http://dx.doi.org/10.2174/1871520620666200807223832]
[http://dx.doi.org/10.2174/1871520620666200807223832]